# TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

> **NCT06297642** · PHASE1 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** TQB2928 injection
- **DRUG:** Penpulimab

## Key facts

- **NCT ID:** NCT06297642
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-24
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit.
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297642, "TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06297642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*